The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes
NCT ID: NCT01389362
Last Updated: 2011-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
16 participants
INTERVENTIONAL
2009-05-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improvement of Insulin Resistance With Traditional Chinese Treatment in Patients With Type 2 Diabetes
NCT00704236
Effects of TCM on Beta-cell Function and Insulin Resistance in High Risk Chinese Individuals for T2D (TCM_PDiab_P01)
NCT04441216
Traditional Chinese Medicine in Individualized Treatment of Patients With Diabetes Symptoms
NCT01844050
Therapeutic Effects of Topical Herbal Medicine -Rhubarb Ointment on Rosacea
NCT05045469
An Innovative Chinese Herbal Formula for Macular Edema
NCT05122702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The abnormal metabolic milieus of hyperglycemia, hyperlipidemia, hypertension, pro-thrombotic state and chronic inflammation in diabetes causes atherosclerosis. A significant proportion of subjects have underlying peripheral arterial disease and neuropathy. These subjects are at great risk of developing infective foot ulceration secondary to impaired vascular supply, sensory loss and minor trauma. Without prompt and proper medical treatment, these infective ulcers will deteriorate leading to gangrene and limb amputation. Age, wound depth, the presence of ischaemia, a low albumin level, and the lack of simultaneous ulceration are the most significant independent predictors of an unfavourable outcome. The conventional management of diabetic foot ulcer includes rest, antibiotic therapy, surgical debridement and good glycemic control. The investigators previously demonstrated that the use of a recipe containing 12 herbs was effective in promoting the healing of severe chronic non-healing diabetic foot ulcers and achieved an 85% of limb preservation. In-vitro and in-vivo studies revealed that 5 out of the 12 herbs were effective in promoting fibroblast proliferation and angiogenesis. To minimize potential drug interactions and adverse effects from multiple components in a recipe of Traditional Chinese Medicine (TCM), the investigators have developed a simplified formula from the 12 herbs consisting of only two herbs.
Many herbs have long been used to treat diabetes mellitus and its complications. In many of these successful attempts Radix Rehmanniae (RR) and Radix Astragali (RA) have frequently been used in combination with other herbs to form complex formulae such as 'blood-house blood stasis-dispelling decoction with additive ingredients' and 'pills of six drugs with Rehmannia'.
Based on our previous in-vitro and in-vivo studies, a new reformulated recipe of herbal medicine has been developed. In this proof-of-concept study, the investigators hypothesize that the novel recipe of herbal medicine will expedite healing of early foot ulcer by promoting vascularisation and granulation as well as modulating inflammatory response. Results will provide valuable insight and understanding of the application of TCM in the management of diabetic foot ulcer, in particular, the effect on angiogenesis and anti-inflammation. New intellectual properties will be developed and provide the foundation for future research. Such an integrated approach from bench to bedside will serve as a model platform for the development of TCM in Hong Kong.
The study will investigate whether the two-herb recipe can increase the wound healing of patients with diabetes mellitus.
Primary outcome:
1. Resolution/progression of foot ulcer based on PEDIS
2. Failure of treatment i.e. no improvement in 6 months, rapid deterioration or emergency surgery required
Secondary outcome:
1. Hospital admission/attendance/stay
2. Metabolic parameters
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chinese Herbal Medicine
2 sachets of Chinese Herbal Medicine to be taken daily
Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)
2 sachets to be taken daily
Placebo arm
2 sachets to be taken daily
Placebo comparator
2 sachets to be taken daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)
2 sachets to be taken daily
Placebo comparator
2 sachets to be taken daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patients attending Diabetic Clinics and/or Podiatry Clinics at the hospitals of the New Territories East Cluster
* Aged between 20 and 75 years old inclusive
* All patients should be on stable dose of medication 4 weeks prior to enrolment
* Written informed consent
* If the patient is a woman of child-bearing potential, she must agree to use adequate method of contraception throughout the study period, unless surgically sterilized.
Exclusion Criteria
* Patients with advanced diabetic eye disease as defined by the history of laser therapy, retinal detachment or vitreous hemorrhage
* Pregnancy, breast feeding, or patient has plans of becoming pregnant during the study period.
* Known allergy to TCM drugs
* Contraindication or intolerance to use of aspirin, statin , ACEI or ARB
* History of major gastrointestinal bleeding in the 5 years prior to consent
* Congestive heart failure of any severity
* Significant cardiovascular disease within 3 months of enrolment including acute coronary syndrome, cardiac revascularization procedure, transient ischemic attack and cerebrovascular accident
* HbA1c ≥ 10%
* Severe liver function impairment (≥ 3 ULN of ALT) and renal impairment (eGFR \< 30 ml/min/1.73 m2)
* Investigational drugs within 30 days of enrolment
* Patient taking any Chinese herbal medicine in the 8 weeks prior to enrolment into the study
* Any other medical conditions that is considered as unsuitable for the study by investigator
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chinese University of Hong Kong
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juliana NA Chan, MBChB, FRCP
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diabetes and Endocrine Centre
Hong Kong SAR, Hong Kong SAR, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ko CH, Yi S, Ozaki R, Cochrane H, Chung H, Lau W, Koon CM, Hoi SW, Lo W, Cheng KF, Lau CB, Chan WY, Leung PC, Chan JC. Healing effect of a two-herb recipe (NF3) on foot ulcers in Chinese patients with diabetes: a randomized double-blind placebo-controlled study. J Diabetes. 2014 Jul;6(4):323-34. doi: 10.1111/1753-0407.12117. Epub 2014 Feb 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRE-2008.581
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.